109.04
+1.23%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Aarey Drugs and Pharmaceuticals
Its shares trade on NSE under the ticker AAREYDRUGS.NS. It has been listed since 8 December 1993. In the fiscal year to 31 March 2026, it reported revenue of ₹4.72bn and net income of ₹39.7m. At that date it held total assets of ₹2.97bn and shareholders' equity of ₹1.50bn.
Aarey Drugs & Pharmaceuticals Ltd. engages in the trade and manufacture of pharmaceutical ingredients, drug intermediates, specialty chemicals, industrial solvents, and chemicals. The company is headquartered in Mumbai, Maharashtra. The firm is also engaged in the trading of industrial solvents and chemicals. The firm is manufacturing intermediates, which include Mono Methyl Urea, Die Methyl Urea, Ortho Para Nitro Anisole, 2 Bromomethyl 1,3 Dioxalane and Uracile. The Company’s API includes Metformin Hydrochloric Acid (HCL), Mefenamic Acid and Doxophylline. The firm's chemical and solvents include aromatics chemicals, chemical acid, chloralkaline, industrial alcohols, industrial ketones, glycols and glycol ethers, fiber intermediates, industrial amines, acetates and esters, industrial oleochemicals, chlorinated solvents, industrial intermediates, industrial olefines, industrial phosphates, industrial fertilizers, industrial monomers and industrial chemicals.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 8 Dec 1993
- Website
- aareydrugs.com ↗
Leadership
Pay as last reported
- Mr. Mihir GhataliaChairman of the Board, Managing Director₹300,000
- Mrs. Mira GhataliaChief Financial Officer
- Mr. Kailash JethliaCompliance Officer, Company Secretary
- Damiyanti GhataliaWoman Director
- Mr. Nimit GhataliaDirector
- Mr. Anil MandalAdditional Director
- Chetan MehtaNon-Executive Independent Director
- Shri. Lalit TulsianiAdditional Non-Executive Independent Director, since 2020
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Aarey Drugs & Pharmaceuticals Ltd manufactures Mono Methyl Urea and Die Methyl Urea in Mumbai, Maharashtra.
- The company produces API Metformin Hydrochloric Acid (HCL) and Mefenamic Acid for the Health Care sector.
- Aarey Drugs trades industrial solvents and chemicals including aromatics and chlorinated solvents.
Weaknesses
- The company has 0 full-time employees in Mumbai, Maharashtra, affecting operational capacity.
- Aarey Drugs lacks manufacturing of specialty chemicals beyond intermediates and APIs.
- The firm's product range does not include consumer pharmaceuticals or medical devices.
Opportunities
- Aarey Drugs can expand into the Indian pharmaceutical market with its API Metformin HCL.
- The company may leverage its chemical intermediates for new industrial applications in India.
- Aarey Drugs could partner with global firms for chemical trading in the Indian market.
Threats
- Aarey Drugs faces competition from established Indian pharmaceutical companies in Mumbai.
- The lack of full-time employees may hinder growth in the Health Care sector.
- Regulatory changes in the Indian pharmaceutical industry could impact Aarey Drugs' operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.